The medical devices sector is typified by frequent change and innovation, in response to problems and issues faced by the healthcare industry. As a result, the sector has seen the emergence of several start-up medtech companies offering disruptive, cutting-edge solutions. Most of these are private companies, where data such as revenue is frequently not disclosed. National estimates for Immucor sales in the US from 2016 to 2022, as well as year-on-year growth rates, can be viewed in GlobalData’s micro revenue report. Buy the report here.

Smarter leaders trust GlobalData

Report-cover

Premium Insights Immucor Inc, United States Revenue

Buy the Report

Premium Insights

The gold standard of business intelligence.

Find out more

Immucor is a provider of transfusion and transplantation diagnostic products. The company develops, manufactures and sells serology-based reagents and instruments for pre-transfusion typing and screening of blood; and assays for pre-transplant typing and screening and post-transplant monitoring. It also offers coagulation products to help determine a patient’s risk of excessive bleeding and antibody count in thrombosis. The company develops molecular and antibody-based assays using its ELISA and xMAP technology. It serves hospitals, donor centers and reference laboratories worldwide. The company markets products directly and through a network of distributors in the US, Belgium, India, Italy, Japan, Portugal, Canada, France, Germany, Spain and the UK and rest of the world. Immucor is headquartered in Norcross, Georgia, the US. Key subsidiaries of Immucor include Sirona Genomics, Immucor, Immucor GTI Diagnostics, Immucor Gamma Benelux and Immucor GTI Diagnostics Holdings.

The key metrics of Immucor related to marketed and pipeline products, ongoing clinical trials, active jobs and publications from 2022 are shown below:

As Immucor is a privately held company, it is not required to disclose its financial information and there is no stock listed on an exchange. GlobalData has access to a proprietary data set containing invoice data from over 2,600 healthcare institutions in the US and is therefore able to use estimations of a company’s revenue and growth to value private companies such as Immucor.

For a detailed understanding of the performance of Immucor, buy the report here.

Premium Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article. 

GlobalData’s revenue report leverages GlobalData’s SKU tracker, which contains real-world, purchasing data from the US healthcare institutions.